# Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma

> **NCT07646717** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (actual)

## Conditions studied

- Intrahepatic Cholangiocarcinoma (Icc)

## Interventions

- **DRUG:** hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors

## Key facts

- **NCT ID:** NCT07646717
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-02-24
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646717, "Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07646717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*